Answers are grounded in this paper and cite their sources.
Suggests targeting SRRM1 improves gemcitabine response in pancreatic cancer, implying new treatment strategies.
This study suggests that SRRM1 may serve as a predictive biomarker for GEM response in pancreatic cancer. Targeting SRRM1 in conjunction with ferroptosis inducers could offer a promising strategy to overcome GEM resistance.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: